ADMA BIOLOGICS, INC. (ADMA) Debt / Equity
- 2026-06-30: Debt/Equity Ratio 0.48.
- 2026-03-31: Debt/Equity Ratio 0.5.
- 2025-12-31: Debt/Equity Ratio 0.15.
- 2025-09-30: Debt/Equity Ratio 0.17.
Complete source-backed debt/equity ratio history.
- Available history
- 2024-12-31 to 2026-06-30
- Data captured
Historical Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2026-06-30 | 0.48 |
| 2026-03-31 | 0.5 |
| 2025-12-31 | 0.15 |
| 2025-09-30 | 0.17 |
| 2024-12-31 | 0.21 |
Annual Debt/Equity Ratio
| Date | Debt/Equity Ratio |
|---|---|
| 2025-12-31 | 0.15 |
| 2024-12-31 | 0.21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |